JP7492687B2 - Ｄｎａ－ｐｋｃｓを阻害するための薬物治療 - Google Patents

Ｄｎａ－ｐｋｃｓを阻害するための薬物治療 Download PDF

Info

Publication number
JP7492687B2
JP7492687B2 JP2020526666A JP2020526666A JP7492687B2 JP 7492687 B2 JP7492687 B2 JP 7492687B2 JP 2020526666 A JP2020526666 A JP 2020526666A JP 2020526666 A JP2020526666 A JP 2020526666A JP 7492687 B2 JP7492687 B2 JP 7492687B2
Authority
JP
Japan
Prior art keywords
endostatin
tumor
cells
composition
etoposide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020526666A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528457A (ja
JP2020528457A5 (enExample
Inventor
ヨンチャン、ルオ
リン、ジア
グオドン、チャン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tsinghua University
Protgen Ltd
Original Assignee
Tsinghua University
Protgen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tsinghua University, Protgen Ltd filed Critical Tsinghua University
Publication of JP2020528457A publication Critical patent/JP2020528457A/ja
Publication of JP2020528457A5 publication Critical patent/JP2020528457A5/ja
Application granted granted Critical
Publication of JP7492687B2 publication Critical patent/JP7492687B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020526666A 2017-07-30 2018-07-27 Ｄｎａ－ｐｋｃｓを阻害するための薬物治療 Active JP7492687B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201710638033 2017-07-30
CN201710638033.2 2017-07-30
CN201710733900 2017-08-24
CN201710733900.0 2017-08-24
PCT/CN2018/097609 WO2019024814A1 (zh) 2017-07-30 2018-07-27 抑制dna依赖蛋白激酶催化亚基的药物

Publications (3)

Publication Number Publication Date
JP2020528457A JP2020528457A (ja) 2020-09-24
JP2020528457A5 JP2020528457A5 (enExample) 2021-09-09
JP7492687B2 true JP7492687B2 (ja) 2024-05-30

Family

ID=65233426

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020526666A Active JP7492687B2 (ja) 2017-07-30 2018-07-27 Ｄｎａ－ｐｋｃｓを阻害するための薬物治療

Country Status (7)

Country Link
US (2) US20200237796A1 (enExample)
EP (1) EP3662922B1 (enExample)
JP (1) JP7492687B2 (enExample)
CN (1) CN110913884B (enExample)
AU (1) AU2018310410B2 (enExample)
CA (1) CA3103035A1 (enExample)
WO (1) WO2019024814A1 (enExample)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518341A (ja) 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
JP2002519010A (ja) 1998-06-30 2002-07-02 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Ｄｎａ−ｐｋの使用法
US20040110671A1 (en) 2002-12-05 2004-06-10 Yongzhang Luo N-terminal modified recombinant human endostatin and its production
JP2009523743A (ja) 2006-01-20 2009-06-25 清華大学 癌治療のための医薬品およびその使用
JP2014510737A (ja) 2011-03-28 2014-05-01 チンファ ユニヴァーシティ 標的細胞による治療薬の取り込みを高めるための方法及び組成物
JP2014531897A (ja) 2011-09-09 2014-12-04 チンファ ユニヴァーシティＴｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ Ａｔｐ結合部位に変異を有するエンドスタチン変異体

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470667B2 (en) * 2002-12-05 2008-12-30 Medgenn (Hong Kong) Ltd Methods of treating cancer using a modified endostatin protein
CN1891717A (zh) * 2005-07-08 2007-01-10 南京大学 内皮抑素的化学修饰方法及其应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002518341A (ja) 1998-06-15 2002-06-25 アーチ・デヴェロップメント・コーポレイション 放射線療法と抗血管形成因子の組み合わせ
JP2002519010A (ja) 1998-06-30 2002-07-02 スローン − ケタリング・インスティテュート・フォー・キャンサー・リサーチ Ｄｎａ−ｐｋの使用法
US20040110671A1 (en) 2002-12-05 2004-06-10 Yongzhang Luo N-terminal modified recombinant human endostatin and its production
JP2009523743A (ja) 2006-01-20 2009-06-25 清華大学 癌治療のための医薬品およびその使用
JP2014510737A (ja) 2011-03-28 2014-05-01 チンファ ユニヴァーシティ 標的細胞による治療薬の取り込みを高めるための方法及び組成物
JP2014531897A (ja) 2011-09-09 2014-12-04 チンファ ユニヴァーシティＴｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ Ａｔｐ結合部位に変異を有するエンドスタチン変異体

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Shun Lu ，A multicenter, open-label, randomized phase II controlled study of rh-endostatin (Endostar) in combination with chemotherapy in previously untreated extensive-stage small-cell lung cancer，J Thorac Oncol，2015年，Vol. 10, No. 1，p. 206-211，doi: 10.1097/JTO.0000000000000343
Tumor Supression by p53 Is Mediated in Part by the Antiangiogenic Activity of Endostatin and Tumstatin，Science's STKE，2006年，354，DOI: 10.1126/stke.3542006pe35

Also Published As

Publication number Publication date
EP3662922A4 (en) 2021-04-07
CN110913884B (zh) 2023-06-06
US20200237796A1 (en) 2020-07-30
AU2018310410B2 (en) 2024-11-14
AU2018310410A1 (en) 2020-03-12
CA3103035A1 (en) 2019-02-07
EP3662922B1 (en) 2025-03-05
JP2020528457A (ja) 2020-09-24
US20240165140A1 (en) 2024-05-23
CN110913884A (zh) 2020-03-24
WO2019024814A1 (zh) 2019-02-07
EP3662922A1 (en) 2020-06-10

Similar Documents

Publication Publication Date Title
Gordon‐Weeks et al. Neutrophils promote hepatic metastasis growth through fibroblast growth factor 2–dependent angiogenesis in mice
CN103154020B (zh) 抗转移疗法中axl信号传导的抑制
JP2014169293A (ja) Ｓｐａｒｃ及びその使用方法
Babaei-Jadidi et al. Mast-cell tryptase release contributes to disease progression in lymphangioleiomyomatosis
Im et al. Regulation of HMGB1 release protects chemoradiotherapy-associated mucositis
Song et al. RNA interference-mediated suppression of TNF-α converting enzyme as an alternative anti-TNF-α therapy for rheumatoid arthritis
Wu et al. Targeting cIAPs attenuates CCl4-induced liver fibrosis by increasing MMP9 expression derived from neutrophils
JP2021180671A (ja) Ｂ１ｓｐ融合タンパク質の治療薬、方法、および使用
EP2935322B1 (en) Angiopoietin-2 specific tie2 receptor
JP7492687B2 (ja) Ｄｎａ－ｐｋｃｓを阻害するための薬物治療
Ishizuka et al. Involvement of the receptor-associated prorenin system in the pathogenesis of human conjunctival lymphoma
CN101688205B (zh) 抗肿瘤药物、药剂、组合物及其用途
US20220125770A1 (en) Combination therapy of alk-positive neoplasia
WO2009014702A2 (en) Cd74 for use in the treatment of cancer and liver toxicity
Sanders Modulation of the Immune Response as a Potential Therapeutic for Glioblastoma
Thomas EVALUATING EVIDENCE FOR THE USE OF PARP INHIBITORS IN CANCERS WITHOUT BRCA1 OR BRCA2 MUTATIONS
CN117959442A (zh) 预防或治疗肺纤维化的试剂及应用
Xiao et al. Synergistic inhibition of APE1 redox activity and ATM activation sensitizes osteosarcoma cells to ionizing radiation by inducing ferroptosis
JP6944373B2 (ja) Ｍｃｊアゴニストおよびそれらに関する使用
WO2024245445A1 (zh) Malt1肿瘤抑制剂、含有其的药物及应用
JP2024058472A (ja) 抗線維化剤、線維症治療用医薬組成物、抗線維化剤の製造方法および抗線維化方法
WO2014035828A2 (en) Inhibition of axl signaling in anti-metastatic therapy
CA3185193A1 (en) Composition comprising ttf-ngr for use in treating soft-tissue sarcoma
WO2021150770A1 (en) Oncogenic trim37 is a targetable epigenetic driver of metastasis and links chemoresistance and metastatic fate in triple-negative breast cancer
Winkles GrB-TWEAK: A Potential Novel Biologic for NSCLC Therapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200401

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210726

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210726

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220510

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220810

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20221206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230606

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230905

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240110

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240409

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240509

R150 Certificate of patent or registration of utility model

Ref document number: 7492687

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150